New research from BenovelentAI supports use of Lilly’s Olumiant in COVID-19

New research from BenovelentAI supports use of Lilly’s Olumiant in COVID-19

Source: 
Pharmaforum
snippet: 

AI and machine learning drug development firm BenevolentAI has highlighted further data supporting its hypothesis that Eli Lilly’s Olumiant (baricitinib) could be a potential treatment for COVID-19.